TrialAdvances in therapy2025

Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed.

Dimos D Mitsikostas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.